Category: Federal Forum Posters
Purpose: Dual antiplatelet therapy (DAPT) is typically used to treat patients with acute coronary syndrome for 12 months. Some studies suggest the benefit of prolonged DAPT in high-risk patients may outweigh bleeding risk, however the optimal duration of DAPT remains unclear, as identifying these patients is challenging. The DAPT score has been proposed as a tool used to predict combined ischemic and bleeding risk for patients receiving DAPT beyond one year after percutaneous coronary intervention (PCI). The purpose of this study is to evaluate the utility of the DAPT score in determining duration of DAPT after PCI in a veteran population.
Methods: This is a quality improvement project utilizing retrospective chart review. Patients who underwent PCI at the Lexington VA Health System from 2010-2015 and received one year of DAPT will be included. Patients will be excluded if they were receiving concomitant therapy with an oral anticoagulant or had a prior stroke. A DAPT risk score will be calculated for all patients using the American College of Cardiology DAPT Risk Calculator. The relationship between DAPT score and risk of major adverse cardiovascular and cerebrovascular events (MACCE) (MI, stroke, and all-cause death), and fatal or major bleeding will be evaluated to determine the utility of the DAPT Risk Calculator in determining duration of DAPT in a veteran population. Other outcomes will include whether there is a relationship between type of antiplatelet agent used, MACCE, and fatal or major bleeding, as well as which patients appear to benefit the most from prolonged DAPT therapy. Lastly, we will examine if there are any opportunities for improvement in the management of patients on DAPT following PCI at the Lexington VA Health System.
Results: not applicable
Conclusion: not applicable
Catherine Ammerman– Student, UK College of Pharmacy, Florence, KY